Stockhub

GlycoMimetics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

3 September 2022

20 August 2022

7 August 2022

  • curprev 11:5311:53, 7 August 2022 >Chris 1,284 bytes +13 No edit summary undo
  • curprev 11:5211:52, 7 August 2022 >Chris 1,271 bytes +16 No edit summary undo
  • curprev 11:4911:49, 7 August 2022 >Chris 1,255 bytes +121 No edit summary undo
  • curprev 11:3611:36, 7 August 2022 172.18.0.4 talk 1,134 bytes +14 No edit summary undo
  • curprev 11:3311:33, 7 August 2022 >Paris 1,120 bytes +1,120 Created page with "GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-..."
Retrieved from "https://stockhub.co/research/GlycoMimetics,_Inc."